ACT Signature Webinars

Nonclinical Abuse Liability Testing of Biologics 

04-17-2019 04:23 PM

Hosted by the American College of Toxicology in Collaboration with the British Toxicology Society, the Society of Toxicologic Pathology, and the Teratology Society

Speaker: Thomas Hudzik, PhD & Christina de Zafra, PhD, DABT

Abstract for Nonclinical Abuse Liability Testing of Biologics:

The misuse of prescription drugs has become an epidemic in the United States and a number of other countries, with consequently enormous socioeconomic impact. The manufacturers of new molecular entities (NMEs) are responsible for evaluating the potential for their candidate drugs to be abused in the intended clinical population or diverted for non-medicinal use. Abuse liability is assessed both nonclinically, in vitro and in animal models, and in human clinical trials. Regulatory guidance has been provided by the FDA and EMA and provides a framework for the conduct of abuse liability assessments; importantly, the guidance does not distinguish between molecules based on therapeutic indication or molecule type (small versus large molecules). This webinar will provide an overview of the regulatory guidance on abuse liability assessment, explain why comprehensive assessments are important for all NMEs, and clarify the distinctions between small and large molecules that reduce the likelihood that large molecules will be abused.

View Webinar Recording

Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and co-host societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.

0 Favorited
1 Files
pdf file
Nonclinical Abuse Liability Testing of Biologics_final.pdf   1.66 MB   1 version
Uploaded - 08-27-2020

Related Entries and Links

No Related Resource entered.